Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
Eighty percent of bladder cancers present as superficial disease. Many are multifocal, and apparently successful treatment is frequently followed by recurrence. The use of monoclonal antibodies (MAbs) to target radiotherapy to these tumors offers great potential, especially since they can be administered directly into the bladder (intravesically) bypassing many of the side effects encountered to date with systemic MAb-based therapy. Implantation of human bladder cancer cell lines in the bladder wall of nude rats results in tumor formation, providing an excellent model to test this. Tumor size can be monitored by X-ray analysis after administration of urograffin. Comparative studies of two murine MAbs, BLCA-8, IgG3, and C1-137, IgG1, against malignant human bladder cancer cells have been performed. Radioimmunoconjugates produced with 125Iodine (125I) have been used for biodistribution studies following administration directly into rat bladder. Radioiodinated intact MAbs or Fabs administered intravesically into nontumor bearing rats did not leak into the systemic circulation and were stable in urine for up to 100 h. Biodistribution studies carried out following intravesical administration of radioimmunoconjugates to tumor-bearing nude rats indicate better tumor uptake of C1-137 than BLCA-8. Further studies to test two-step intravesical administration of biotinylated MAb followed by radioiodinated streptavidin are in progress. Our studies indicate that the C1-137 MAb may have considerable potential for intravesical radioimmunotherapy of patients with superficial bladder tumors.
Russell
P J
PJ
Oncology Research Centre, Prince of Wales Hospital, Randwick, NSW, Australia.
Davis
K
K
Kingsley
E
E
Humphreys
J
J
Hanley
J
J
O'Grady
H
H
Pearce
N
N
D000283:Administration, Intravesical; D000818:Animals; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D004195:Disease Models, Animal; D005069:Evaluation Studies as Topic; D006801:Humans; D016499:Radioimmunotherapy / Q000379:methods*; D051381:Rats; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy*
D000911:Antibodies, Monoclonal